Subjects:
BloodWork, Free Research Articles, Lymphoid Neoplasia
Topics:
cd138, multiple myeloma
A 69-year-old man with a history of CD138− plasma cell myeloma (PCM) who received chemotherapy regimens and stem cell transplant presented for bone marrow biopsy, which revealed sheets of atypical plasma cells with abundant amphophilic cytoplasm, occasional binucleation, and distinct perinuclear hof (panels A-B; original magnification ×100, Wright-Giemsa stain [A] and ×40, hematoxylin and eosin stain [B]). The neoplastic cells strongly expressed CD38 and MUM1, but were negative for CD138 by immunostains (panels C-E; original magnification ×40). Flow cytometry analysis showed that they expressed bright CD38 and monotypic cytoplasmic κ, but were negative for CD138, CD19, CD27, CD45, CD56, and CD117 (panels F-J). Fluorescence in situ hybridization was positive for deletion of TP53 and CCND1, gain of CKS1B and FGFR3, and monosomy 13. Next-generation sequencing studies detected TP53, KRAS, TET2, RUNX1, SRSF2, and BRAF gene mutations. The findings were diagnostic of a refractory CD138− PCM. The patient developed tumor lysis syndrome and a retroperitoneal hematoma and died of uncontrolled bleeding. / Lack of CD138 expression renders a challenge in diagnosis and minimal residual disease detection in patients with PCM, especially after treatment with anti-CD38 antibodies when CD38 expression is lost. Recognizing the presence of CD138− PCM combined with morphology and other plasma cell markers, such as CD38 and MUM1, will be helpful for a correct diagnosis.
View largeDownload PPT

A 69-year-old man with a history of CD138− plasma cell myeloma (PCM) who received chemotherapy regimens and stem cell transplant presented for bone marrow biopsy, which revealed sheets of atypical plasma cells with abundant amphophilic cytoplasm, occasional binucleation, and distinct perinuclear hof (panels A-B; original magnification ×100, Wright-Giemsa stain [A] and ×40, hematoxylin and eosin stain [B]). The neoplastic cells strongly expressed CD38 and MUM1, but were negative for CD138 by immunostains (panels C-E; original magnification ×40). Flow cytometry analysis showed that they expressed bright CD38 and monotypic cytoplasmic κ, but were negative for CD138, CD19, CD27, CD45, CD56, and CD117 (panels F-J). Fluorescence in situ hybridization was positive for deletion of TP53 and CCND1, gain of CKS1B and FGFR3, and monosomy 13. Next-generation sequencing studies detected TP53, KRAS, TET2, RUNX1, SRSF2, and BRAF gene mutations. The findings were diagnostic of a refractory CD138− PCM. The patient developed tumor lysis syndrome and a retroperitoneal hematoma and died of uncontrolled bleeding.

Lack of CD138 expression renders a challenge in diagnosis and minimal residual disease detection in patients with PCM, especially after treatment with anti-CD38 antibodies when CD38 expression is lost. Recognizing the presence of CD138− PCM combined with morphology and other plasma cell markers, such as CD38 and MUM1, will be helpful for a correct diagnosis.

A 69-year-old man with a history of CD138− plasma cell myeloma (PCM) who received chemotherapy regimens and stem cell transplant presented for bone marrow biopsy, which revealed sheets of atypical plasma cells with abundant amphophilic cytoplasm, occasional binucleation, and distinct perinuclear hof (panels A-B; original magnification ×100, Wright-Giemsa stain [A] and ×40, hematoxylin and eosin stain [B]). The neoplastic cells strongly expressed CD38 and MUM1, but were negative for CD138 by immunostains (panels C-E; original magnification ×40). Flow cytometry analysis showed that they expressed bright CD38 and monotypic cytoplasmic κ, but were negative for CD138, CD19, CD27, CD45, CD56, and CD117 (panels F-J). Fluorescence in situ hybridization was positive for deletion of TP53 and CCND1, gain of CKS1B and FGFR3, and monosomy 13. Next-generation sequencing studies detected TP53, KRAS, TET2, RUNX1, SRSF2, and BRAF gene mutations. The findings were diagnostic of a refractory CD138− PCM. The patient developed tumor lysis syndrome and a retroperitoneal hematoma and died of uncontrolled bleeding. / Lack of CD138 expression renders a challenge in diagnosis and minimal residual disease detection in patients with PCM, especially after treatment with anti-CD38 antibodies when CD38 expression is lost. Recognizing the presence of CD138− PCM combined with morphology and other plasma cell markers, such as CD38 and MUM1, will be helpful for a correct diagnosis.
View largeDownload PPT

A 69-year-old man with a history of CD138− plasma cell myeloma (PCM) who received chemotherapy regimens and stem cell transplant presented for bone marrow biopsy, which revealed sheets of atypical plasma cells with abundant amphophilic cytoplasm, occasional binucleation, and distinct perinuclear hof (panels A-B; original magnification ×100, Wright-Giemsa stain [A] and ×40, hematoxylin and eosin stain [B]). The neoplastic cells strongly expressed CD38 and MUM1, but were negative for CD138 by immunostains (panels C-E; original magnification ×40). Flow cytometry analysis showed that they expressed bright CD38 and monotypic cytoplasmic κ, but were negative for CD138, CD19, CD27, CD45, CD56, and CD117 (panels F-J). Fluorescence in situ hybridization was positive for deletion of TP53 and CCND1, gain of CKS1B and FGFR3, and monosomy 13. Next-generation sequencing studies detected TP53, KRAS, TET2, RUNX1, SRSF2, and BRAF gene mutations. The findings were diagnostic of a refractory CD138− PCM. The patient developed tumor lysis syndrome and a retroperitoneal hematoma and died of uncontrolled bleeding.

Lack of CD138 expression renders a challenge in diagnosis and minimal residual disease detection in patients with PCM, especially after treatment with anti-CD38 antibodies when CD38 expression is lost. Recognizing the presence of CD138− PCM combined with morphology and other plasma cell markers, such as CD38 and MUM1, will be helpful for a correct diagnosis.

Close modal

For additional images, visit the ASH Image Bank, a reference and teaching tool that is continually updated with new atlas and case study images. For more information, visit http://imagebank.hematology.org.

© 2019 by The American Society of Hematology
2019
Sign in via your Institution